Blood-Based Biomarkers for Neurological Disorders

Neurological disorders remain among the most pressing challenges in medicine, often requiring early and ongoing detection to improve outcomes. While cerebrospinal fluid (CSF) has long been the gold standard for biomarker discovery, blood-based biomarkers (BBBs) are now emerging as a scalable, less invasive alternative. Advances in proteomics have made it possible to detect pathology of the central nervous system through the blood, unlocking powerful potential for routine screening, longitudinal tracking and population-scale research.

Fill out the form below to download the white paper

In this white paper, explore how next-generation technologies – SomaScan™ Assay, KREX™ arrays and CyTOF™ platform – are being used to interrogate the proteome, immunoproteome and immune cells in blood. Through real-world case studies across Alzheimer’s disease, autism, schizophrenia and more, see how these tools are revealing disease-specific signatures. Gain insights into integrating these approaches into your workflow and explore what’s next for clinical adoption of BBBs.

Get your free copy
Fill out the form to download the full white paper and learn how advanced blood-based profiling is transforming neurological research and diagnostics.